# EDGAR Filing Document

**Accession Number:** 0001890004
**File Stem:** 0000899243-23-007436
**Filing Date:** 2023-3
**Character Count:** 10171
**Document Hash:** a6be671c09af1b98d4ab981ce4f78709
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-007436.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0000899243-23-007436

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230303

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** NSV Partners III GP LLC
- **CENTRAL INDEX KEY:** 0001889601
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40928
- **FILM NUMBER:** 23714652

**BUSINESS ADDRESS:**
- **STREET 1:** 500 WEST PUTNAM AVE
- **STREET 2:** SUITE 400
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
- **BUSINESS PHONE:** 2126885100

**MAIL ADDRESS:**
- **STREET 1:** 500 WEST PUTNAM AVE
- **STREET 2:** SUITE 400
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** NSV Partners III LP
- **CENTRAL INDEX KEY:** 0001890004
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40928
- **FILM NUMBER:** 23714653

**BUSINESS ADDRESS:**
- **STREET 1:** 500 WEST PUTNAM AVE
- **STREET 2:** SUITE 400
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
- **BUSINESS PHONE:** 2126885100

**MAIL ADDRESS:**
- **STREET 1:** 500 WEST PUTNAM AVE
- **STREET 2:** SUITE 400
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ventyx Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001851194
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 832996852
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 662 ENCINITAS BLVD., STE. 250
- **CITY:** ENCINITAS
- **STATE:** CA
- **ZIP:** 92024
- **BUSINESS PHONE:** (858) 945-2393

**MAIL ADDRESS:**
- **STREET 1:** 662 ENCINITAS BLVD., STE. 250
- **CITY:** ENCINITAS
- **STATE:** CA
- **ZIP:** 92024

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>NSV Partners III LP<br><sub>(Last) (First) (Middle)</sub><br>500 WEST PUTNAM AVENUE, SUITE 400<br><sub>(Street)</sub><br>GREENWICH, CT 06830<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Ventyx Biosciences, Inc. [ VTYX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>NSV Partners III GP LLC<br><sub>(Last) (First) (Middle)</sub><br>500 WEST PUTNAM AVENUE, SUITE 400<br><sub>(Street)</sub><br>GREENWICH, CT 06830<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Ventyx Biosciences, Inc. [ VTYX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-03 |  | J<sup>(1)</sup> |  | 559367 | D | $0.00 | 12415419 | I | See Footnotes<sup>(2)(3)(4)(5)(6)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) Life & Tech distributed these shares to their members on a pro rata basis, for no consideration.

(2) Consists of (i) 5,576,174 shares owned by NSV Investments I, LP, (ii) 965,752 shares owned by NSV Master Limited Partnership II, LP, (iii) 888,440 shares owned by NSV 2019 Opportunities Fund, LP, (iv) 768,073 shares owned by NSV 2018 New Horizons Fund, LP, (v) 661,632 shares owned by Life & Tech, (vi) 1,096,827 shares owned by NSV Investments III, LP, (vii) 998,099 shares owned by NSV Investments II, LP, (viii) 434,423 shares owned by New Science Ventures, LLC, (ix) 133,629 shares owned by NSV Growth Opportunities Fund, LP, (x) 84,232 shares owned by New Science Ventures Fund III, LP, (xi) 74,032 shares owned by NSV 2017 Opportunities Fund, LP, (xii) 51,624 shares owned by NSV 2018 Opportunities Fund, LP, (xiii) 39,926 shares owned by NSV 2016 Opportunities Fund, LP, (xiv) 26,555 shares owned by New Science Ventures Fund III (Offshore), LP, (xv) 10,980 shares owned by NSV 2016 Opportunities Fund (Offshore), LP, (xvi) 565,739 shares owned by NSV Partners III, LP,

(3) (Continued from footnote 2) and (xvii) 186,107 shares owned by NSV Partners II, LLC (collectively, the "NSV Funds"). The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein.

(4) NSV Partners III, LP, is the general partner of Life & Tech, NSV 2018 New Horizons Fund LP, NSV Investments I, LP, NSV 2018 Opportunities Fund, LP, NSV 2019 Opportunities Fund, LP, NSV Growth Opportunities Fund, LP, NSV Investments III, LP, and NSV Investments II, LP, (collectively, the "NSV Partners III Funds").

(5) NSV Partners II, LLC, is the general partner of New Science Ventures Fund III, LP, New Science Ventures Fund III (Offshore), LP, NSV 2016 Opportunities Fund, LP, NSV 2016 Opportunities Fund (Offshore), LP, NSV 2017 Opportunities Fund, LP, and NSV Master Limited Partnership II, LP (collectively, the "NSV Partners II Funds").

(6) Somasundaram Subramaniam is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners III, LP is general partner. Mr. Subramaniam disclaims beneficial ownership over the shares owned by each of the NSV Funds, except to the extent of his pecuniary interest therein. Mr. Subramaniam is the majority member and managing member NSV Partners II, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners II, LLC is general partner. Mr. Subramaniam is a director of the Issuer and files separate Section 16 reports.

**Signature:** /s/ NSV Partners III, LP, By: Brenda Marex, Chief Financial Officer  
**Date:** 2023-03-07

**Signature:** /s/ NSV Partners III GP, LLC, By: Brenda Marex, Chief Financial Officer  
**Date:** 2023-03-07

**Signature:** /s/ NSV Investments I, LP, By: Brenda Marex, Chief Financial Officer  
**Date:** 2023-03-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**